Torrent’s Entry Into Indian Trade Generics Signals Strategy Shift
US Launches Still Held Back
Faced with a slowdown in the US from a lack of regulatory approvals, Torrent Pharma is looking at alternate growth strategies. Its entry into the trade generics segment in India, joining other pharma majors, is one to be watched as it marks a strategic shift.
You may also be interested in...
Generics Industry Fails To Match Last Year’s Growth In First Quarter
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
Novartis Faces Another Challenge To Entresto In India
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar
Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect